Price (delayed)
$0.9439
Market cap
$51.46M
P/E Ratio
11.8
Dividend/share
N/A
EPS
$0.08
Enterprise value
-$20.21M
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.
There are no recent dividends present for SPRO.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.